Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...

Medtronic PLC closed $2.15 below its 52-week high ($91.49), which the company reached on September 4th.

A month has gone by since the last earnings report for Medtronic (MDT). Shares have added about 0.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up ...

Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...

Finland’s capital city, Helsinki, is building the world’s largest heat pump to keep as many as 30,000 homes warm in the winter while reducing carbon emissions. The pump can operate at ...

New Zealand Society for the Study of Diabetes (NZSSD) welcomes Pharmac’s decision to fund continuous glucose monitors and insulin pumps, which allow automated insulin delivery, for people with type 1 ...

Pharmac – Te Pātaka Whaioranga has decided to fund continuous glucose monitors (CGMs), insulin pumps, and insulin pump consumables for people with type 1 diabetes from 1 October 2024.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

In April, Medtronic obtained FDA approval for another new product, Inceptiv, a spinal cord stimulator for treating chronic pain. The device can automatically adjust the therapy — a unique feature — to ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

Medtronic plc (NYSE: MDT) is a leading global medical device maker in the medical sector. Its innovative and critical medical ...

Medtronic plc (NYSE:MDT ... Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal ...